This is a summary of the European public assessment report (EPAR) for Karvea. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Karvea.
Therapeutic Indication
Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type\-2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Therapeutic Area (MeSH)
ATC Code
C09CA04
ATC Item
N/A
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| irbesartan | N/A | irbesartan |
EMA Name
Karvea
Medicine Name
Karvea
Aliases
N/ANo risk management plan link.
